148 related articles for article (PubMed ID: 36789566)
1. Sample size calculation for the combination test under nonproportional hazards.
Cheng H; He J
Biom J; 2023 Apr; 65(4):e2100403. PubMed ID: 36789566
[TBL] [Abstract][Full Text] [Related]
2. Comparison of survival distributions in clinical trials: A practical guidance.
Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
[TBL] [Abstract][Full Text] [Related]
3. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
Royston P; B Parmar MK
Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
[TBL] [Abstract][Full Text] [Related]
4. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
5. Sample size calculation for logrank test and prediction of number of events over time.
Lu K
Pharm Stat; 2021 Mar; 20(2):229-244. PubMed ID: 32909395
[TBL] [Abstract][Full Text] [Related]
6. Sample size calculation for two-arm trials with time-to-event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions.
Phadnis MA; Mayo MS
Biom J; 2021 Oct; 63(7):1406-1433. PubMed ID: 34272897
[TBL] [Abstract][Full Text] [Related]
7. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
Phadnis MA; Wetmore JB; Mayo MS
Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
[TBL] [Abstract][Full Text] [Related]
8. Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints.
Cortés Martínez J; Geskus RB; Kim K; Melis GG
BMC Med Res Methodol; 2021 May; 21(1):99. PubMed ID: 33957892
[TBL] [Abstract][Full Text] [Related]
9. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
Royston P; Parmar MK
Trials; 2014 Aug; 15():314. PubMed ID: 25098243
[TBL] [Abstract][Full Text] [Related]
10. The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?
Rauch G; Brannath W; Brückner M; Kieser M
Methods Inf Med; 2018 May; 57(3):89-100. PubMed ID: 29719915
[TBL] [Abstract][Full Text] [Related]
11. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
Royston P; Parmar MK
BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
[TBL] [Abstract][Full Text] [Related]
12. Sample size calculation for the augmented logrank test in randomized clinical trials.
Hattori S; Komukai S; Friede T
Stat Med; 2022 Jun; 41(14):2627-2644. PubMed ID: 35319100
[TBL] [Abstract][Full Text] [Related]
13. Critical review of oncology clinical trial design under non-proportional hazards.
Ananthakrishnan R; Green S; Previtali A; Liu R; Li D; LaValley M
Crit Rev Oncol Hematol; 2021 Jun; 162():103350. PubMed ID: 33989767
[TBL] [Abstract][Full Text] [Related]
14. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
Wang Z; Zhang Q; Xue A; Whitmore J
Pharm Stat; 2024; 23(3):325-338. PubMed ID: 38152873
[TBL] [Abstract][Full Text] [Related]
15. Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology.
Ristl R; Ballarini NM; Götte H; Schüler A; Posch M; König F
Pharm Stat; 2021 Jan; 20(1):129-145. PubMed ID: 32830428
[TBL] [Abstract][Full Text] [Related]
16. Sample size and power for the weighted log-rank test and Kaplan-Meier based tests with allowance for nonproportional hazards.
Yung G; Liu Y
Biometrics; 2020 Sep; 76(3):939-950. PubMed ID: 31797363
[TBL] [Abstract][Full Text] [Related]
17. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
[TBL] [Abstract][Full Text] [Related]
18. Versatile tests for window mean survival time.
Paukner M; Chappell R
Stat Med; 2022 Aug; 41(19):3720-3736. PubMed ID: 35611993
[TBL] [Abstract][Full Text] [Related]
19. Randomized two-stage optimal design for interval-censored data.
Shan G
J Biopharm Stat; 2022 Mar; 32(2):298-307. PubMed ID: 34890525
[TBL] [Abstract][Full Text] [Related]
20. Impact of a non-constant baseline hazard on detection of time-dependent treatment effects: a simulation study.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2021 Aug; 21(1):177. PubMed ID: 34454428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
